Apr 05, 2012, 10.58 PM IST | Source: CNBC-TV18

Biocon expands its R&D facility in Bangalore

Bio-pharma major Biocon on expansion mode.

Kiran Mazumdar-Shaw, CMD, Biocon

Bio-pharma major Biocon is on an expansion mode. The biotech major plans to invest close to Rs 100 crore on its new research and development center located in Bangalore, with a window for future investments going up to Rs 200 crore in next few years.

Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.

Biocon stock price

On July 14, 2014, Biocon closed at Rs 478.30, down Rs 3.4, or 0.71 percent. The 52-week high of the share was Rs 553.70 and the 52-week low was Rs 286.60.

The company's trailing 12-month (TTM) EPS was at Rs 16.43 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 29.11. The latest book value of the company is Rs 120.89 per share. At current value, the price-to-book value of the company is 3.96.

Set email alert for


video of the day

See 8000 Nifty by Dec, bullish energy, cap goods: Religare

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.